REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
612.49 USD   +0.84%
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Transthyretin Amyloidosis
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment

05/20/2022 | 01:27pm EDT

By Michael Dabaie


The Food and Drug Administration said it granted to Regeneron Pharmaceuticals Inc. approval of Dupixent to treat inflammatory disorder chronic immune disorder eosinophilic esophagitis.

The FDA approval is for adults and pediatric patients 12 and older.

Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus. Common symptoms include difficulty swallowing, difficulty eating, and food getting stuck in the esophagus.

The FDA originally approved Dupixent in 2017. The drug is approved for moderate-to-severe atopic dermatitis and as an add-on maintenance treatment for certain types of moderate-to-severe asthma, as well as an add-on maintenance treatment in adults with inadequately controlled chronic rhinosinusitis with nasal polyposis.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

05-20-22 1527ET

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 0.84% 612.49 Delayed Quote.-3.01%
SANOFI 5.02% 100.56 Real-time Quote.13.52%
All news about REGENERON PHARMACEUTICALS, INC.
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Tra..
MT
06/24Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based ..
AQ
06/15REGENERON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/14TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global ..
CI
06/14RBC Cuts Price Target on Regeneron Pharmaceuticals to $647 From $658, Noting Risk to Ey..
MT
06/09Alnylam Pharmaceuticals Says Cemdisiran Product Meets Primary Endpoint of Immunoglobuli..
MT
06/09ALNYLAM : Encouraging Results From Phase 2 Cemdisiran Study in IgA Nephropathy
DJ
06/08Regeneron Pharmaceuticals, Inc. - FDA APPROVES DUPIXENT (DUPILUMAB) AS FIRST BIOLOGIC M..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 756 M - -
Net income 2022 4 039 M - -
Net cash 2022 8 626 M - -
P/E ratio 2022 16,8x
Yield 2022 -
Capitalization 65 993 M 65 993 M -
EV / Sales 2022 4,88x
EV / Sales 2023 4,28x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 612,49 $
Average target price 679,24 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-3.01%63 230
GILEAD SCIENCES, INC.-13.12%77 153
VERTEX PHARMACEUTICALS33.22%69 645
WUXI APPTEC CO., LTD.-13.42%41 016
BIONTECH SE-48.69%30 052
GENMAB A/S-17.76%19 922